Search Follow us

Genkyotex (GKTX )

Business description

Genticel and privately-held company Genkyotex have signed a contribution agreement to form a combined entity focused on the development of NOX inhibitors for fibrosis and other indications. The transaction has been approved by Genticel’s shareholders.

Termination of coverage

Termination | Pharmaceutical & healthcare | 07/08/2018

Edison Investment Research is terminating coverage on Genkyotex (GKTX). Please note you should no longer rely on any previous research or estimates for this company. All forecasts should now be considered redundant.

Edison's research is freely available. We will never ask for your credit card details and you do not need to register. By downloading this research you are agreeing to our terms and conditions, which you can read in full here.

Stock data

Market cap.€130m
Last close€1.670
High / Low (52 weeks)€1.9 / €1.5
Stock market listingEU
Forecast net cash (€m)4.1
Forecast gearing ratio (%)N/A
TeamHealthcare
SectorPharmaceutical & healthcare

Price performance

%1m3m12m
Actual5.014.4(10.2)
Relative *3.015.0(16.2)

* % Relative to local index

Company news

Genkyotex

Mon, 07 May 2018 05:26:15 GMT

Genkyotex

Tue, 15 May 2018 12:56:15 GMT

Genkyotex

Tue, 28 Feb 2017 18:06:05 GMT

Genkyotex

Wed, 16 May 2018 12:33:45 GMT

Genkyotex

Tue, 27 Jun 2017 17:03:45 GMT